{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:58:58Z","timestamp":1784159938679,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01005-9","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T22:01:51Z","timestamp":1730930511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Leishmania tarentolae as a platform for the production of vaccines against viral pathogens"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-1179","authenticated-orcid":false,"given":"Marta","family":"Zimna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-4254","authenticated-orcid":false,"given":"Ewelina","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"5245021","DOI":"10.1155\/2017\/5245021","volume":"2017","author":"NI Nii-Trebi","year":"2017","unstructured":"Nii-Trebi, N. I. Emerging and Neglected Infectious Diseases: Insights, Advances, and Challenges. Biomed. Res. Int. 2017, 5245021 (2017).","journal-title":"Biomed. Res. Int."},{"key":"1005_CR2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nature06536","volume":"451","author":"KE Jones","year":"2008","unstructured":"Jones, K. E. et al. Global trends in emerging infectious diseases. Nature 451, 990\u2013993 (2008).","journal-title":"Nature"},{"key":"1005_CR3","doi-asserted-by":"crossref","unstructured":"Angevaare, M. J., Joling, K. J. & Smalbrugge, M. The Effects of the 2020 COVID-19 Lockdown on Mood, Behavior, and Social and Cognitive Functioning in Older Long-Term Care Residents. J. Am. Med. Dir. Assoc. 23(9), 1608.e9\u20131608.e18 (2022).","DOI":"10.1016\/j.jamda.2022.07.003"},{"key":"1005_CR4","doi-asserted-by":"publisher","first-page":"12333","DOI":"10.3390\/ijerph191912333","volume":"19","author":"AE Barbouzas","year":"2022","unstructured":"Barbouzas, A. E., Malli, F., Daniil, Z. & Gourgoulianis, K. Long-Term Impact of COVID-19 Pandemic in Sleep Quality and Lifestyle in Young Adults. Int. J. Environ. Res. Public Health 19, 12333 (2022).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1005_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-022-14806-1","volume":"22","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee, S. et al. Identifying long-term effects of SARS-CoV-2 and their association with social determinants of health in a cohort of over one million COVID-19 survivors. BMC Public Health 22, 1\u201310 (2022).","journal-title":"BMC Public Health"},{"key":"1005_CR6","doi-asserted-by":"crossref","unstructured":"Robert, M. A., Stewart-ibarra, A. M. & Estallo, E. L. Climate change and viral emergence: evidence from Aedes-borne arboviruses. Curr. Opin. Virol. 40, 41\u201347 (2020).","DOI":"10.1016\/j.coviro.2020.05.001"},{"key":"1005_CR7","first-page":"149","volume":"19","author":"J Whitehorn","year":"2019","unstructured":"Whitehorn, J. & Yacoub, S. Global warming and arboviral infections. Clin. Med. J. R. Coll. Physicians Lond. 19, 149\u2013152 (2019).","journal-title":"Clin. Med. J. R. Coll. Physicians Lond."},{"key":"1005_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/imr.12098","volume":"255","author":"BS Graham","year":"2013","unstructured":"Graham, B. S. Advances in antiviral vaccine development. Immunol. Rev. 255, 230\u2013242 (2013).","journal-title":"Immunol. Rev."},{"key":"1005_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.smim.2013.05.004","volume":"25","author":"CA MacLennan","year":"2013","unstructured":"MacLennan, C. A. Vaccines for low-income countries. Semin. Immunol. 25, 114\u2013123 (2013).","journal-title":"Semin. Immunol."},{"key":"1005_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/21645515.2016.1260795","volume":"13","author":"I Legastelois","year":"2017","unstructured":"Legastelois, I. et al. Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules. Hum. Vaccines Immunother. 13, 947\u2013961 (2017).","journal-title":"Hum. Vaccines Immunother."},{"key":"1005_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.vaccine.2012.10.103","volume":"31","author":"S Ozawa","year":"2012","unstructured":"Ozawa, S., Mirelman, A., Stack, M. L., Walker, D. G. & Levine, O. S. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine 31, 96\u2013108 (2012).","journal-title":"Vaccine"},{"key":"1005_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1017\/S0031182000049027","volume":"90","author":"KR Wallbanks","year":"1985","unstructured":"Wallbanks, K. R., Maazoun, R., Canning, E. U. & Rioux, J. A. The identity of Leishmania tarentolae Wenyon 1921. Parasitology 90, 67\u201378 (1985).","journal-title":"Parasitology"},{"key":"1005_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1017\/S0031182000014347","volume":"12","author":"CM Wenyon","year":"1920","unstructured":"Wenyon, C. M. Observations on the intestinal protozoa of three Egyptian Lizards, with a note on a Cell-invading fungus. Parasitology 12, 350\u2013365 (1920).","journal-title":"Parasitology"},{"key":"1005_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1046-5928(02)00001-3","volume":"25","author":"R Breitling","year":"2002","unstructured":"Breitling, R. et al. Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Expr. Purif. 25, 209\u2013218 (2002).","journal-title":"Protein Expr. Purif."},{"key":"1005_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2859-11-97","volume":"11","author":"S Klatt","year":"2012","unstructured":"Klatt, S. & Konthur, Z. Secretory signal peptide modification for optimized antibody-fragment expression-secretion in Leishmania tarentolae. Microb. Cell Fact. 11, 1 (2012).","journal-title":"Microb. Cell Fact."},{"key":"1005_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/j.1460-2075.1995.tb07089.x","volume":"14","author":"M Wiese","year":"1995","unstructured":"Wiese, M., Ilg, T., Lottspeich, F. & Overath, P. Ser\/Thr-rich repetitive motifs as targets for phosphoglycan modifications in Leishmania mexicana secreted acid phosphatase. EMBO J. 14, 1067\u20131074 (1995).","journal-title":"EMBO J."},{"key":"1005_CR17","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/nar\/gkr834","volume":"40","author":"F Raymond","year":"2012","unstructured":"Raymond, F. et al. Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res 40, 1131\u20131147 (2012).","journal-title":"Nucleic Acids Res"},{"key":"1005_CR18","unstructured":"LEXSY \u2013 Eukaryotic Protein Expression. Jena Bioscience brochure: https:\/\/www.jenabioscience.com\/images\/b3e879b381\/Lexsy_brochure_web.pdf."},{"key":"1005_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12033-009-9213-5","volume":"43","author":"G Basile","year":"2009","unstructured":"Basile, G. & Peticca, M. Recombinant Protein Expression in Leishmania tarentolae. Mol. Biotechnol. 43, 273\u2013278 (2009).","journal-title":"Mol. Biotechnol."},{"key":"1005_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2859-9-29","volume":"9","author":"H Dortay","year":"2010","unstructured":"Dortay, H. & Mueller-Roeber, B. A highly efficient pipeline for protein expression in Leishmania tarentolae using infrared fluorescence protein as marker. Microb. Cell Fact. 9, 1\u201310 (2010).","journal-title":"Microb. Cell Fact."},{"key":"1005_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.exppara.2010.12.006","volume":"127","author":"A Bolhassani","year":"2011","unstructured":"Bolhassani, A. et al. Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies. Exp. Parasitol. 127, 637\u2013645 (2011).","journal-title":"Exp. Parasitol."},{"key":"1005_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/jobm.200710111","volume":"47","author":"C Fritsche","year":"2007","unstructured":"Fritsche, C., Sitz, M., Weiland, N., Breitling, R. & Pohl, H. D. Characterization of the growth behavior of Leishmania tarentolae - A new expression system for recombinant proteins. J. Basic Microbiol. 47, 384\u2013393 (2007).","journal-title":"J. Basic Microbiol."},{"key":"1005_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/jobm.200700389","volume":"48","author":"C Fritsche","year":"2008","unstructured":"Fritsche, C., Sitz, M., Wolf, M. & Pohl, H. D. Development of a defined medium for heterologous expression in Leishmania tarentolae. J. Basic Microbiol. 48, 488\u2013495 (2008).","journal-title":"J. Basic Microbiol."},{"key":"1005_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pep.2015.08.024","volume":"116","author":"A Bolhassani","year":"2015","unstructured":"Bolhassani, A., Shirbaghaee, Z., Agi, E. & Davoudi, N. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1. Protein Expr. Purif. 116, 7\u201311 (2015).","journal-title":"Protein Expr. Purif."},{"key":"1005_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pep.2005.03.004","volume":"42","author":"S Kushnir","year":"2005","unstructured":"Kushnir, S., Gase, K., Breitling, R. & Alexandrov, K. Development of an inducible protein expression system based on the protozoan host Leishmania tarentolae. Protein Expr. Purif. 42, 37\u201346 (2005).","journal-title":"Protein Expr. Purif."},{"key":"1005_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-1-61779-433-9_15","volume":"824","author":"T Niimi","year":"2012","unstructured":"Niimi, T. Recombinant protein production in the eukaryotic protozoan parasite Leishmania tarentolae: A review. Methods Mol. Biol. 824, 307\u2013315 (2012).","journal-title":"Methods Mol. Biol."},{"key":"1005_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.procbio.2019.08.019","volume":"87","author":"T Aparecida","year":"2019","unstructured":"Aparecida, T. et al. Application of the LEXSY Leishmania tarentolae system as a recombinant protein expression platform: A review. Process Biochem 87, 164\u2013173 (2019).","journal-title":"Process Biochem"},{"key":"1005_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1039\/D0MO00043D","volume":"16","author":"SN Mule","year":"2020","unstructured":"Mule, S. N. et al. Protein glycosylation in: Leishmania spp. Mol. Omi. 16, 407\u2013424 (2020).","journal-title":"Mol. Omi."},{"key":"1005_CR29","first-page":"1","volume":"12","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. The Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection. Front. Immunol. 12, 1\u201312 (2021).","journal-title":"Front. Immunol."},{"key":"1005_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pep.2009.07.005","volume":"68","author":"HP Phan","year":"2009","unstructured":"Phan, H. P., Sugino, M. & Niimi, T. The production of recombinant human laminin-332 in a Leishmania tarentolae expression system. Protein Expr. Purif. 68, 79\u201384 (2009).","journal-title":"Protein Expr. Purif."},{"key":"1005_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep30627","volume":"6","author":"K Grzyb","year":"2016","unstructured":"Grzyb, K. et al. Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex. Sci. Rep. 6, 1\u201311 (2016).","journal-title":"Sci. Rep."},{"key":"1005_CR32","doi-asserted-by":"publisher","first-page":"e01422","DOI":"10.1128\/AAC.01422-19","volume":"64","author":"F Rodriguez","year":"2020","unstructured":"Rodriguez, F. et al. In vitro and in vivo characterization of potent antileishmanial methionine aminopeptidase 1 inhibitors. Antimicrob. Agents Chemother. 64, e01422\u201319 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1005_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-018-1254-2","volume":"20","author":"N Dumpa","year":"2019","unstructured":"Dumpa, N. et al. Stability of Vaccines. AAPS PharmSciTech 20, 1\u201311 (2019).","journal-title":"AAPS PharmSciTech"},{"key":"1005_CR34","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1586\/erv.09.20","volume":"8","author":"D Chen","year":"2009","unstructured":"Chen, D. & Kristensen, D. Opportunities and challenges of developing thermostable vaccines. Expert Rev. Vaccines 8, 547\u2013557 (2009).","journal-title":"Expert Rev. Vaccines"},{"key":"1005_CR35","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1016\/j.vaccine.2014.07.092","volume":"32","author":"C Pion","year":"2014","unstructured":"Pion, C. et al. Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae. Vaccine 32, 5570\u20135576 (2014).","journal-title":"Vaccine"},{"key":"1005_CR36","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1001\/jama.2020.21869","volume":"324","author":"TM Uyeki","year":"2020","unstructured":"Uyeki, T. M. High-risk Groups for Influenza Complications. JAMA J. Am. Med. Assoc. 324, 2334 (2020).","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"1005_CR37","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.1016\/j.vaccine.2006.05.079","volume":"24","author":"A Flahault","year":"2006","unstructured":"Flahault, A., Vergu, E., Coudeville, L. & Grais, R. F. Strategies for containing a global influenza pandemic. Vaccine 24, 6751\u20136755 (2006).","journal-title":"Vaccine"},{"key":"1005_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.vaccine.2012.10.111","volume":"31","author":"J Partridge","year":"2013","unstructured":"Partridge, J. & Kieny, M. P. Global production capacity of seasonal influenza vaccine in 2011. Vaccine 31, 728\u2013731 (2013).","journal-title":"Vaccine"},{"key":"1005_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","volume":"94","author":"PC Soema","year":"2015","unstructured":"Soema, P. C., Kompier, R., Amorij, J. P. & Kersten, G. F. A. Current and next generation influenza vaccines: Formulation and production strategies. Eur. J. Pharm. Biopharm. 94, 251\u2013263 (2015).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"1005_CR40","unstructured":"World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 53 (WHO, 2021)."},{"key":"1005_CR41","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.2174\/1567201814666170125120917","volume":"14","author":"A Bolhassani","year":"2017","unstructured":"Bolhassani, A., Davoudi, N., Motevalli, F. & Agi, E. Comparison of HCV Core and CoreE1E2 Virus-Like Particles Generated by Stably Transfected Leishmania tarentolae for the Stimulation of Th1 Immune Responses in Mice. Curr. Drug Deliv. 14, 1040\u20131049 (2017).","journal-title":"Curr. Drug Deliv."},{"key":"1005_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-016-0460-4","volume":"15","author":"A Czarnota","year":"2016","unstructured":"Czarnota, A. et al. Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus. Microb. Cell Fact. 15, 1\u201312 (2016).","journal-title":"Microb. Cell Fact."},{"key":"1005_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8020294","volume":"8","author":"A Czarnota","year":"2020","unstructured":"Czarnota, A. et al. Specific antibodies induced by immunization with hepatitis B virus-like particles carrying hepatitis C virus envelope glycoprotein 2 epitopes show differential neutralization efficiency. Vaccines 8, 1\u201319 (2020).","journal-title":"Vaccines"},{"key":"1005_CR44","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1016\/j.vaccine.2018.10.034","volume":"36","author":"J Sal\u00e1t","year":"2018","unstructured":"Sal\u00e1t, J. et al. Development and testing of a new tick-borne encephalitis virus vaccine candidate for veterinary use. Vaccine 36, 7257\u20137261 (2018).","journal-title":"Vaccine"},{"key":"1005_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4149\/av_2020_212","volume":"64","author":"J Sal\u00e1t","year":"2020","unstructured":"Sal\u00e1t, J. & R\u016f\u017eek, D. Tick-borne encephalitis in domestic animals. Acta Virol. 64, 226\u2013232 (2020).","journal-title":"Acta Virol."},{"key":"1005_CR46","doi-asserted-by":"crossref","unstructured":"Lehrer, A. & Holbrook, M. Tick-borne Encephalitis Vaccines. J. Bioterror. Biodef. Suppl 1, 1\u201313 (2011).","DOI":"10.4172\/2157-2526.S1-003"},{"key":"1005_CR47","doi-asserted-by":"publisher","first-page":"105511","DOI":"10.1016\/j.antiviral.2022.105511","volume":"209","author":"M Zimna","year":"2023","unstructured":"Zimna, M. et al. Functional characterization and immunogenicity of a novel vaccine candidate against tick-borne encephalitis virus based on Leishmania-derived virus-like particles. Antivir. Res 209, 105511 (2023).","journal-title":"Antivir. Res"},{"key":"1005_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3332\/ecancer.2019.975","volume":"13","author":"AM Beddoe","year":"2019","unstructured":"Beddoe, A. M. Elimination of cervical cancer: Challenges for developing countries. Ecancermedicalscience 13, 1\u20136 (2019).","journal-title":"Ecancermedicalscience"},{"key":"1005_CR49","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.3390\/curroncol29050303","volume":"29","author":"GK Shapiro","year":"2022","unstructured":"Shapiro, G. K. HPV Vaccination: An Underused Strategy for the Prevention of Cancer. Curr. Oncol. 29, 3780\u20133792 (2022).","journal-title":"Curr. Oncol."},{"key":"1005_CR50","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","volume":"20","author":"KT Simms","year":"2019","unstructured":"Simms, K. T. et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020\u201399: a modelling study. Lancet Oncol. 20, 394\u2013407 (2019).","journal-title":"Lancet Oncol."},{"key":"1005_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4161\/hv.5.10.9518","volume":"5","author":"MH Einstein","year":"2009","unstructured":"Einstein, M. H. et al. Comparison of the immunogenicity and safety of CervarixTM and Gardasil\u00ae human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5, 705\u2013719 (2009).","journal-title":"Hum. Vaccin."},{"key":"1005_CR52","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00420-020-01543-4","volume":"93","author":"FM Hofmann","year":"2020","unstructured":"Hofmann, F. M., Olawumi, E., Michaelis, M., St\u00f6\u00dfel, U. & Hofmann, F. Significance of norovirus in occupational health: a review of published norovirus outbreaks in Central and Northern Europe. Int. Arch. Occup. Environ. Health 93, 911\u2013923 (2020).","journal-title":"Int. Arch. Occup. Environ. Health"},{"key":"1005_CR53","doi-asserted-by":"publisher","first-page":"105259","DOI":"10.1016\/j.micpath.2021.105259","volume":"161","author":"Y Liao","year":"2021","unstructured":"Liao, Y. et al. Global prevalence of norovirus in cases of acute gastroenteritis from 1997 to 2021: An updated systematic review and meta-analysis. Microb. Pathog. 161, 105259 (2021).","journal-title":"Microb. Pathog."},{"key":"1005_CR54","unstructured":"Baric, R., Carolina, N., Kang, C., College, C. M. & Lee, B. Global Burden of Norovirus and Prospects for Vaccine Development Table of Contents (CDC, 2015)."},{"key":"1005_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-021-01677-1","volume":"20","author":"M Panasiuk","year":"2021","unstructured":"Panasiuk, M. et al. Immunization with Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies. Microb. Cell Fact. 20, 1\u201311 (2021).","journal-title":"Microb. Cell Fact."},{"key":"1005_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-022-01357-1","volume":"20","author":"M Panasiuk","year":"2022","unstructured":"Panasiuk, M. et al. Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy. J. Nanobiotechnol. 20, 1\u201313 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"1005_CR57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1099\/vir.0.81995-0","volume":"88","author":"M Breton","year":"2007","unstructured":"Breton, M., Zhao, C., Ouellette, M., Tremblay, M. J. & Papadopoulou, B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J. Gen. Virol. 88, 217\u2013225 (2007).","journal-title":"J. Gen. Virol."},{"key":"1005_CR58","doi-asserted-by":"publisher","first-page":"6372","DOI":"10.1128\/IAI.73.10.6372-6382.2005","volume":"73","author":"M Breton","year":"2005","unstructured":"Breton, M., Tremblay, M. J., Ouellette, M. & Papadopoulou, B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 73, 6372\u20136382 (2005).","journal-title":"Infect. Immun."},{"key":"1005_CR59","unstructured":"World Health Organization. Epidemiological fact sheet HIV statistics, globally and by WHO region, 2023 (WHO, 2023)."},{"key":"1005_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002729","volume":"16","author":"J Jones","year":"2019","unstructured":"Jones, J., Sullivan, P. S. & Curran, J. W. Progress in the HIV epidemic: Identifying goals and measuring success. PLoS Med 16, 1\u20138 (2019).","journal-title":"PLoS Med"},{"key":"1005_CR61","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/imt.12.110","volume":"4","author":"M Salehi","year":"2012","unstructured":"Salehi, M. et al. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. Immunotherapy 4, 1107\u20131120 (2012).","journal-title":"Immunotherapy"},{"key":"1005_CR62","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/10717544.2013.801534","volume":"20","author":"S Hosseinzadeh","year":"2013","unstructured":"Hosseinzadeh, S. et al. A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. Drug Deliv. 20, 190\u2013198 (2013).","journal-title":"Drug Deliv."},{"key":"1005_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17795\/ijcp-3991","volume":"8","author":"Z Shirbaghaee","year":"2015","unstructured":"Shirbaghaee, Z., Bolhassani, A., Mirshafiey, A., Motevalli, F. & Zohrei, N. A live vector expressing HPV16 L1 generates an adjuvant-induced antibody response in-vivo. Int. J. Cancer Manag. 8, 1\u20136 (2015).","journal-title":"Int. J. Cancer Manag."},{"key":"1005_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molimm.2019.04.009","volume":"111","author":"N Ansari","year":"2019","unstructured":"Ansari, N. et al. A non-pathogenic Leishmania tarentolae vector based- HCV polytope DNA vaccine elicits potent and long lasting Th1 and CTL responses in BALB\/c mice model. Mol. Immunol. 111, 152\u2013161 (2019).","journal-title":"Mol. Immunol."},{"key":"1005_CR65","doi-asserted-by":"publisher","first-page":"106546","DOI":"10.1016\/j.phrs.2022.106546","volume":"186","author":"S Epis","year":"2022","unstructured":"Epis, S. et al. Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19. Pharmacol. Res. 186, 106546 (2022).","journal-title":"Pharmacol. Res."},{"key":"1005_CR66","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1039\/D0AN02286A","volume":"146","author":"J Castillo-Le\u00f3n","year":"2021","unstructured":"Castillo-Le\u00f3n, J., Trebbien, R., Castillo, J. J. & Svendsen, W. E. Commercially available rapid diagnostic tests for the detection of high priority pathogens: Status and challenges. Analyst 146, 3750\u20133776 (2021).","journal-title":"Analyst"},{"key":"1005_CR67","doi-asserted-by":"publisher","first-page":"736530","DOI":"10.3389\/fmicb.2021.736530","volume":"12","author":"I Varotto-Boccazzi","year":"2021","unstructured":"Varotto-Boccazzi, I. et al. Epidemic Preparedness\u2014Leishmania tarentolae as an Easy-to-Handle Tool to Produce Antigens for Viral Diagnosis: Application to COVID-19. Front. Microbiol. 12, 736530 (2021).","journal-title":"Front. Microbiol."},{"key":"1005_CR68","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jviromet.2013.05.018","volume":"193","author":"C Baechlein","year":"2013","unstructured":"Baechlein, C., Meemken, D., Pezzoni, G., Engemann, C. & Grummer, B. Expression of a truncated hepatitis E virus capsid protein in the protozoan organism Leishmania tarentolae and its application in a serological assay. J. Virol. Methods 193, 238\u2013243 (2013).","journal-title":"J. Virol. Methods"},{"key":"1005_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jviromet.2015.11.006","volume":"228","author":"K Fischer","year":"2016","unstructured":"Fischer, K. et al. Expression, characterisation and antigenicity of a truncated Hendra virus attachment protein expressed in the protozoan host Leishmania tarentolae. J. Virol. Methods 228, 48\u201354 (2016).","journal-title":"J. Virol. Methods"},{"key":"1005_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-016-0437-3","volume":"15","author":"L Sanchez-Garcia","year":"2016","unstructured":"Sanchez-Garcia, L. et al. Recombinant pharmaceuticals from microbial cells: A 2015 update. Microb. Cell Fact. 15, 1\u20137 (2016).","journal-title":"Microb. Cell Fact."},{"key":"1005_CR71","doi-asserted-by":"crossref","unstructured":"Tripathi, N. K. & Shrivastava, A. Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. Front. Bioeng. Biotechnol. 7, 420 (2019).","DOI":"10.3389\/fbioe.2019.00420"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01005-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01005-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01005-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T23:02:33Z","timestamp":1730934153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01005-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01005-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}